AnaptysBio ( (ANAB) ) has released its Q2 earnings. Here is a breakdown of the information AnaptysBio presented to its investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AnaptysBio, Inc. is a clinical-stage biotechnology company specializing in innovative immunology therapeutics for autoimmune and inflammatory diseases. The company recently released its financial results for the second quarter of 2025, highlighting significant progress in its clinical trials and collaborations.
AnaptysBio reported positive data from its Phase 2b rheumatoid arthritis trial for rosnilimab, a pathogenic T cell depleter, and completed enrollment for its Phase 2 ulcerative colitis trial. The company is also advancing its pipeline with ongoing Phase 1 trials for ANB033 and ANB101, and plans to initiate a Phase 1b cohort for ANB033 in celiac disease by the end of 2025. Additionally, AnaptysBio anticipates a $75 million milestone from GSK as Jemperli approaches $1 billion in global sales.
Financially, AnaptysBio reported collaboration revenue of $22.3 million for the second quarter, a significant increase from the previous year, driven by royalties from Jemperli and a license agreement with Vanda Pharmaceuticals. The company also repurchased shares worth $55.5 million, maintaining a cash runway through 2027. Despite a net loss of $38.6 million for the quarter, this represents an improvement from the previous year’s loss.
Looking ahead, AnaptysBio remains focused on advancing its clinical trials and leveraging its collaborations to achieve key milestones. The company’s management expresses confidence in the potential of its pipeline to address unmet needs in immunology therapeutics.